Literature DB >> 25586008

Irritable bowel syndrome is significantly associated with somatisation in 840 patients, which may drive bloating.

P Patel1, P Bercik, D G Morgan, C Bolino, M I Pintos-Sanchez, P Moayyedi, A C Ford.   

Abstract

BACKGROUND: Psychological factors may influence persistence and perceived severity of symptoms in irritable bowel syndrome (IBS). Literature suggests that somatisation is associated with IBS. However, the relationship between IBS subtype, symptoms of IBS and somatisation is unclear. AIM: To examine this issue in a large cohort of secondary care patients.
METHODS: Demographic and gastrointestinal (GI) symptom data were collected from 4224 adult patients via the Rome III questionnaire. Somatisation data were collected using the patient health questionnaire-12. Mean somatisation score and number of somatic symptoms were compared between IBS patients and controls with minimal GI symptoms, and between IBS subtypes using analysis of variance. Effect of level of somatisation on symptom frequency was compared according to IBS subtype using a χ(2) test.
RESULTS: 840 patients met Rome III criteria for IBS, controls were 2137 patients with GI symptoms without IBS. Mean somatisation scores and number of somatic symptoms were higher in IBS vs. controls (P < 0.001), and in mixed stool pattern IBS (IBS-M), vs. IBS with constipation (IBS-C) or diarrhoea (IBS-D) (P < 0.001). High levels of somatisation were more prevalent in IBS-M (31.7%) vs. IBS-C (22.5%) or IBS-D (20.8%) (P = 0.003). For all IBS subtypes, high levels of somatisation were associated with a greater frequency of bloating or abdominal distension prior to logistic regression.
CONCLUSIONS: IBS is strongly associated with higher levels of somatisation, particularly IBS-M. Bloating may be associated with higher levels of somatisation, perhaps explaining why it can be difficult to treat.
© 2015 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2015        PMID: 25586008     DOI: 10.1111/apt.13074

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  14 in total

1.  The Prevalence and Impact of Overlapping Rome IV-Diagnosed Functional Gastrointestinal Disorders on Somatization, Quality of Life, and Healthcare Utilization: A Cross-Sectional General Population Study in Three Countries.

Authors:  Imran Aziz; Olafur S Palsson; Hans Törnblom; Ami D Sperber; William E Whitehead; Magnus Simrén
Journal:  Am J Gastroenterol       Date:  2017-11-14       Impact factor: 10.864

2.  Enhancing Diagnostic Performance of Symptom-Based Criteria for Irritable Bowel Syndrome by Additional History and Limited Diagnostic Evaluation.

Authors:  Ruchit Sood; Michael Camilleri; David J Gracie; Matthew J Gold; Natalie To; Graham R Law; Alexander C Ford
Journal:  Am J Gastroenterol       Date:  2016-08-02       Impact factor: 10.864

3.  Irritable Bowel Syndrome.

Authors:  Kristen Ronn Weaver; Gail DʼEramo Melkus; Wendy A Henderson
Journal:  Am J Nurs       Date:  2017-06       Impact factor: 2.220

Review 4.  Psychological comorbidity in gastrointestinal diseases: Update on the brain-gut-microbiome axis.

Authors:  Hannibal Person; Laurie Keefer
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2020-12-14       Impact factor: 5.067

5.  Microbial signatures in post-infectious irritable bowel syndrome--toward patient stratification for improved diagnostics and treatment.

Authors:  Jonna Jalanka; Anne Salonen; Susana Fuentes; Willem M de Vos
Journal:  Gut Microbes       Date:  2015

Review 6.  Diagnosis of Irritable Bowel Syndrome: Role of Potential Biomarkers.

Authors:  Ivana Plavšić; Goran Hauser; Mladenka Tkalčić; Sanda Pletikosić; Nermin Salkić
Journal:  Gastroenterol Res Pract       Date:  2015-06-11       Impact factor: 2.260

7.  Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies.

Authors:  W D Chey; L S Dove; D A Andrae; P S Covington
Journal:  Aliment Pharmacol Ther       Date:  2017-03-22       Impact factor: 8.171

8.  Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome.

Authors:  Vivek C Goodoory; Cho Ee Ng; Christopher J Black; Alexander C Ford
Journal:  Aliment Pharmacol Ther       Date:  2022-02-15       Impact factor: 9.524

9.  Patients with Multiple Functional Gastrointestinal Disorders (FGIDs) Show Increased Illness Severity: A Cross-Sectional Study in a Tertiary Care FGID Specialty Clinic.

Authors:  Sabrina Berens; Felicitas Engel; Annika Gauss; Jonas Tesarz; Wolfgang Herzog; Beate Niesler; Esther Stroe-Kunold; Rainer Schaefert
Journal:  Gastroenterol Res Pract       Date:  2020-01-28       Impact factor: 2.260

10.  Altered Structural Covariance of Insula, Cerebellum and Prefrontal Cortex Is Associated with Somatic Symptom Levels in Irritable Bowel Syndrome (IBS).

Authors:  Cecilia Grinsvall; Lukas Van Oudenhove; Patrick Dupont; Hyo Jin Ryu; Maria Ljungberg; Jennifer S Labus; Hans Törnblom; Emeran A Mayer; Magnus Simrén
Journal:  Brain Sci       Date:  2021-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.